Cáncer de colonanálisis del costo de enfermedad para los estadios III yIV en Cansercoop IPS

  1. Sanabria Rojas, Andrea 1
  2. Martinez, Jose Ignacio 2
  3. Díaz Rojas, Jorge Augusto 3
  1. 1 Medical Pharmacy Ltda.
  2. 2 Cansercoop, precooperativa de servicios médicos en cáncer, Bogotá, D. C., Colombia.
  3. 3 Departamento de Farmacia, Universidad Nacional de Colombia, Bogotá, Colombia, A. A. 14490.
Revista:
Revista Colombiana de Ciencias Químico-Farmacéuticas

ISSN: 1909-6356 0034-7418

Ano de publicación: 2009

Volume: 38

Número: 2

Páxinas: 193-214

Tipo: Artigo

Outras publicacións en: Revista Colombiana de Ciencias Químico-Farmacéuticas

Resumo

The cancer colon has an increased incidence in Colombia and is a leading causes of mortality and morbidity in this group of diseases with a high economic and emotional burden, from the standpoint of economic impact there is little information in the Colombian context, for this reason, this work makes a case study in a health institution providing services, applying the methodology of “Cost of Illness” based on the prevalence of disease. Aim: To estimate the whole costs, both direct and indirect to cancer colon; establishing a distribution resources to iii and iv stages. Method: analysis cost of Illness was used in patients were diagnosed as having both iii and iv stages with cancer colon, from January 2005 to October 2007; checking a base data in cansercoop ips. Results: 79 people were identified, 44 (iii stage) and 35 (iv stage), 59.9% of all of them are women up to 60 years old and 58.2% belong to Salud Total. The total cost was $ 348.254.762, 98.4% were direct costs and 1.59% were indirect costs. Average cost for each patient was $ 1.700.816 (49.288-11.529.013), iii stage and $ 7.653.742 (13.523-70.354.423), iv stage. 65.66% are medicines. Conclusions: the total costs, both iii and iv stages were $ 77.143.347 and $ 271.111.415 in iii stage and $182.570.717 in iv stage. This analysis can be considered as a preliminary study; however it means a step to subsequent economic health assessments.